Retifanlimab
- Generic Name
- Retifanlimab
- Brand Names
- Zynyz
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2079108-44-2
- Unique Ingredient Identifier
- 2Y3T5IF01Z
- Background
Retifanlimab is a humanized IgG4 kappa monoclonal antibody that binds to the programmed death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells...
- Indication
Retifanlimab is indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma.
- Associated Conditions
- Metastatic Locally Advanced Merkel Cell Carcinoma, Recurrent, locally advanced Merkel Cell Carcinoma
- Associated Therapies
- -
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
- Conditions
- Interventions
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 308
- Registration Number
- NCT04472429
- Locations
- 🇺🇸
Sansum Clinic, Santa Barbara, California, United States
🇫🇷Chu Besancon Hospital Jean Minjoz, Besançon, France
🇺🇸Texas Oncology-Wichita Falls Texoma Cancer Center, Wichita Falls, Texas, United States
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
- Conditions
- Interventions
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 300
- Registration Number
- NCT04463771
- Locations
- 🇺🇸
Advent Health Medical Group-Orlando 2501, Orlando, Florida, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute Hospital, Tampa, Florida, United States
🇺🇸Alaska Womens Cancer Care Akwcc, Anchorage, Alaska, United States
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
- First Posted Date
- 2019-12-19
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 583
- Registration Number
- NCT04205812
- Locations
- 🇹🇷
Trakya Universitesi Tip Fakultesi, Edirne, Turkey
🇿🇦Wits Clinical Research, Johannesburg, South Africa
🇺🇦Kherson Regional Oncologic Dispensary, Kherson, Ukraine
INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT04203511
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
- Conditions
- Interventions
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT03920839
A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Incyte Biosciences Japan GK
- Target Recruit Count
- 18
- Registration Number
- NCT03910530
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa, Japan
🇯🇵National Cancer Center Hospital, Chuo Ku, Japan
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 121
- Registration Number
- NCT03679767
- Locations
- 🇺🇸
Texas Oncology - Waco, Waco, Texas, United States
🇦🇹LKH Graz, Graz, Austria
🇺🇸California Cancer Associates for Research and Excellence, Inc., San Marcos, California, United States
A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 107
- Registration Number
- NCT03599713
- Locations
- 🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸Upmc Cancercenter, Pittsburgh, Pennsylvania, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 94
- Registration Number
- NCT03597295
- Locations
- 🇩🇰
Vejle Hospital, Vejle, Denmark
🇫🇷Centre Hospitalier Universitaire de Besancon, Besancon, France
🇺🇸Maryland Oncology Hematology P.A., Rockville, Maryland, United States
INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 83
- Registration Number
- NCT03589651
- Locations
- 🇺🇸
Rutgers Cancer Institute of Nj, New Brunswick, New Jersey, United States
🇺🇸Upmc Cancercenter, Pittsburgh, Pennsylvania, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.